Ohshima E, Takami H, Sato H, Obase H, Miki I, Ishii A, Karasawa A, Kubo K
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Company, Ltd., Shizuoka-ken, Japan.
J Med Chem. 1992 Sep 4;35(18):3394-402. doi: 10.1021/jm00096a016.
A series of 11-[[2-[(arylsulfonyl)amino]ethyl]thio]-6,11- dihydrodibenz[b,e]oxepin-2-carboxylic acids and related derivatives were synthesized. The compounds were tested for their antagonizing effects on guinea pig platelet TXA2/PGH2 receptors. Structure-activity relationships are discussed. (+/-)-11-[[2-[(Styrylsulfonyl)amino]ethyl]-thio]-6,11- dihydrodibenz[b,e]oxepin-2-carboxylic acid (41) and (+/-)-11-[[2-[(phenylsulfonyl)amino]ethyl]thio]-6,11- dihydrodibenz[b,e]thiepin-2-carboxylic acid (4af) were the most promising compounds with K(i) values of 6.5 +/- 0.29 and 3.7 +/- 0.31 nM, respectively, for the TXA2/PGH2 receptor. These compounds also significantly inhibited U-46619-induced guinea pig platelet aggregation ex vivo (10 mg/kg po). Compound 41 was resolved into its optically active form. The (-)-isomer was 60-fold more potent than the (+)-isomer in the TXA2/PGH2 receptor binding assay. Some compounds tested in this study showed both TXA2/PGH2 receptor antagonizing and TXA2 synthase inhibitory effects.
合成了一系列11-[[2-[(芳基磺酰基)氨基]乙基]硫代]-6,11-二氢二苯并[b,e]氧杂环庚三烯-2-羧酸及其相关衍生物。测试了这些化合物对豚鼠血小板TXA2/PGH2受体的拮抗作用。讨论了构效关系。(±)-11-[[2-[(苯乙烯基磺酰基)氨基]乙基]硫代]-6,11-二氢二苯并[b,e]氧杂环庚三烯-2-羧酸(41)和(±)-11-[[2-[(苯基磺酰基)氨基]乙基]硫代]-6,11-二氢二苯并[b,e]硫杂环庚三烯-2-羧酸(4af)是最有前景的化合物,对TXA2/PGH2受体的K(i)值分别为6.5±0.29和3.7±0.31 nM。这些化合物还显著抑制了U-46619诱导的豚鼠血小板离体聚集(口服10 mg/kg)。化合物41被拆分为其光学活性形式。在TXA2/PGH2受体结合试验中,(-)-异构体的活性比(+)-异构体高60倍。本研究中测试的一些化合物同时显示出TXA2/PGH2受体拮抗作用和TXA2合酶抑制作用。